Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Mirvaso Generic Name & Formulations
Legal Class
Rx
General Description
Brimonidine tartrate 0.33%; topical gel; contains propylene glycol.
Pharmacological Class
Alpha-2 agonist.
How Supplied
Gel—30g (tube or pump), 45g (tube)
Manufacturer
Generic Availability
NO
Mirvaso Indications
Indications
Persistent (nontransient) facial erythema of rosacea.
Mirvaso Dosage and Administration
Adult
≥18yrs: apply a pea-sized amount once daily to each of the five areas of the face (forehead, chin, nose, each cheek); spread gel smoothly and evenly in a thin layer. Wash hands after use.
Children
<18yrs: not established.
Mirvaso Contraindications
Not Applicable
Mirvaso Boxed Warnings
Not Applicable
Mirvaso Warnings/Precautions
Warnings/Precautions
Not for oral, ophthalmic, or intravaginal use. Avoid eyes, lips, irritated skin, or open wounds. Depression. Cerebral or coronary insufficiency. Raynaud's phenomenon. Orthostatic hypotension. Thrombangiitis obliterans. Scleroderma. Sjögrens syndrome. Severe or unstable cardiovascular disease. Pregnancy (Cat.B). Nursing mothers: not recommended.
Mirvaso Pharmacokinetics
See Literature
Mirvaso Interactions
Interactions
Caution with beta-blockers, other antihypertensives, cardiac glycosides. Consider possibility of additive effects with CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Concomitant MAOIs may affect the metabolism and uptake of circulating amines; caution.
Mirvaso Adverse Reactions
Adverse Reactions
Erythema, flushing, burning sensation, contact dermatitis; systemic adverse reactions (eg, bradycardia, hypotension, dizziness), local vasomotor reactions (eg, pallor and excessive whitening, hypersensitivity [discontinue if significant]).
Mirvaso Clinical Trials
See Literature
Mirvaso Note
Not Applicable
Mirvaso Patient Counseling
See Literature
Images
